Kessler Topaz Meltzer announces April 13, 2026 deadline for lead plaintiff applications.

Kessler Topaz Meltzer & Check, LLP has recently taken legal action against uniQure N.V. (QURE) by filing a securities fraud class action lawsuit on behalf of investors who bought or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, inclusive of that period. The lawsuit, referred to as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was brought to the United States District Court for the Southern District of New York.

Investors who purchased or otherwise acquired uniQure ordinary shares during the specified Class Period can aspire to be the lead plaintiff for the class by contacting the Court no later than April 13, 2026. In case you bought QURE ordinary shares within the mentioned time frame and incurred losses, you are advised to communicate with KTMC attorney Jonathan Naji, Esq. at the given contact details for assistance.

The lawsuit revolves around uniQure, a biotechnology company involved in the development of gene therapies for rare diseases, including Huntington’s disease (HD). The leading drug candidate of uniQure is AMT-130, a gene therapy designed to decelerate the advancement of HD. Allegations suggest that uniQure misled investors about the Phase I/II clinical trials of AMT-130 during the Class Period and misrepresented details relating to the Biologics License Application (BLA) submission to the FDA for the employment of AMT-130 for HD patients.

The complaint contends that throughout the Class Period, Defendants of uniQure made deceptive statements about the company’s business and operations, concealing important adverse facts. They misrepresented the FDA’s approval of the Pivotal Study design and the possibility of BLA submission delays due to additional studies. As a result, the statements made by Defendants lacked a solid foundation.

Investors who purchased QURE shares between September 24, 2025, and October 31, 2025, have the opportunity to file for lead plaintiff status by the lead plaintiff deadline on April 13, 2026. KTMC is available for a cost-free case evaluation and supports investors in retaining their preferred counsel or taking no action.

Investors in uniQure N.V. are encouraged to seek more information from Kessler Topaz Meltzer & Check, LLP, a prominent U.S. law firm specializing in securities fraud class actions and global investor protection. The firm has a track record of handling substantial recoveries in securities litigation and is recognized for its expertise in this area. For additional details about Kessler Topaz Meltzer & Check, LLP, visit their offices in Pennsylvania and California.